Today were released iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB)‘s weekly net flows. The ETF registered $769.15M weekly asset inflows for 9.91% increase, reaching $8527.09M last week. The chart of iShares NASDAQ Biotechnology Index (ETF) shows positive weekly setup. In the net flows calculation is not included the performance of the etf but only share redemptions (outflows) and share purchases (inflows). Net inflows create excess cash for managers to invest, which theoretically creates demand for the etf’s holdings. The ETF decreased 0.61% or $1.78 on November 11, hitting $288. About 2.66 million shares traded hands or 25.47% up from the average. iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) has risen 4.38% since April 12, 2016 and is uptrending. It has underperformed by 0.60% the S&P500.
The ETF’s YTD performance is -24.02%, the 1 year is -21.01% and the 3 year is 7.85%.
The ETF’s average P/E ratio is 19.74, the price to book is 3.62, the price to sales is 5.22 and the price to cashflow is 10.04. iShares NASDAQ Biotechnology Index (ETF) is in the ETF category: , is part of the fund family and currently has $ net assets. It was started on 1/1/0001. The fund’s top holdings are: Biogen Inc. for 8.14% of assets, Gilead Sciences Inc. for 8.02%, Amgen Inc. for 7.79%, Celgene Corporation for 7.78%, Regeneron Pharmaceuticals Inc. for 7.12%, Illumina Inc. for 4.29%, Alexion Pharmaceuticals Inc. for 3.87%, Vertex Pharmaceuticals Incorpor for 3.67%, Mylan N.V. for 3.57%, Incyte Corporation for 3.11%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as 0% yield.
More notable recent iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) news were published by: Fool.com which released: “2 Reasons Why the iShares NASDAQ Biotechnology Index (ETF) Tumbled 11% in October” on November 07, 2016, also Investorplace.com with their article: “3 Big Stock Charts: iShares NASDAQ Biotechnology Index (ETF) (IBB …” published on November 09, 2016, Etfdailynews.com published: “These ETFs Are The Best And Worst Performers Since Trump’s Victory” on November 10, 2016. More interesting news about iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) were released by: Investorplace.com and their article: “The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is at a Critical Level” published on October 17, 2016 as well as Foxbusiness.com‘s news article titled: “Biotech ETFs Unwind Political Risk After Trump Victory” with publication date: November 11, 2016.
IBB Company Profile
iShares Nasdaq Biotechnology Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index consists of securities of NASDAQ-listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, and which also meet other eligibility criteria. The Index is one of the eight sub-indices of the NASDAQ Composite, which measures all common stocks listed on The NASDAQ Stock Market, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.